Sarepta reported a challenging fourth quarter with total revenue declining 33% year-over-year to $442.9 million, primarily due to the suspension of ELEVIDYS shipments to non-ambulatory patients in the U.S. Despite the quarterly loss, the company strengthened its capital structure through debt refinancing and expects to be profitable and cash-flow positive in 2026.

Sarepta's Q3 2025 revenues fell 15% to $399.4 million due to reduced ELEVIDYS sales. The company posted a net loss of $179.9 million and a non-GAAP loss of $12.9 million. PMO therapies and gene therapy ELEVIDYS contributed to the revenue mix.

Sarepta Therapeutics delivered strong financial results in Q2 2025, with total revenues increasing by 68% year-over-year to $611.1 million. This growth was primarily fueled by a significant increase in ELEVIDYS net product revenue following its expanded label approval. The company also reported GAAP net income of $196.9 million and non-GAAP net income of $215.2 million, alongside positive cash flow for the quarter.

Sarepta Therapeutics delivered robust revenue growth in Q1 2025, fueled by a surge in ELEVIDYS sales. However, significant R&D investments, including a major licensing agreement with Arrowhead, led to a substantial net loss.

Sarepta Therapeutics posted total revenue of $658.4 million in Q4 2024, a 66% increase year-over-year. The company achieved GAAP net income of $159.0 million and non-GAAP net income of $206.0 million. The growth was largely fueled by ELEVIDYS sales, which accounted for $384.2 million in revenue. Operating income improved significantly to $161.7 million.